

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 65865

**Title:** Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?

**Reviewer's code:** 05523900

**Position:** Peer Reviewer

**Academic degree:** MD, MS

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-03-17

**Reviewer chosen by:** Man Liu

**Reviewer accepted review:** 2021-03-19 15:23

**Reviewer performed review:** 2021-03-19 15:40

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

Good review article, needs some language polishing.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 65865

**Title:** Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?

**Reviewer's code:** 00034151

**Position:** Editorial Board

**Academic degree:** FAASLD, MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** South Korea

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-03-17

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-18 06:18

**Reviewer performed review:** 2021-03-23 05:32

**Review time:** 4 Days and 23 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors well summarized up-to-date information between gut microbiota and inflammatory bowel disease focusing on fecal microbiota transplantation (FMT). However, the title and contents are not coherent since control of gut microbiota is not confined to FMT. So, it is recommended to add other measures to control gut dysbiosis, including probiotics, prebiotics, and postbiotics, etc.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 65865

**Title:** Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?

**Reviewer's code:** 00034179

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Academic Research, Research Scientist

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-03-17

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-17 10:15

**Reviewer performed review:** 2021-03-30 08:12

**Review time:** 12 Days and 21 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

This is a well written minireview which discuss the gut microbiota in inflammatory bowel disease (IBD) and gut microbiota-derived metabolites, especially short chain fatty acids (SCFAs). Moreover, fecal microbiota transplantation (FMT) as a novel therapeutic option in IBD, is discussed. However, more information is needed about the future therapeutic options for IBD, in particular on the synthetic human gut microbiome. Regarding this point, I suggest to consider the review of Minjeong Kang et al. (Int. J. Mol. Sci. 2020, 21, 8744). These data are important also taking into account the title given to the minireview. For this purpose, I would suggest to reduce and join the sections of the microbiota-based interventions in a single paragraph: "The effect of FMT on IBD". Therefore, the current manuscript could greatly benefit from inclusion of the data required, when available

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 65865

**Title:** Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?

**Reviewer's code:** 04091933

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor, Senior Researcher

**Reviewer's Country/Territory:** Russia

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-03-17

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-17 08:41

**Reviewer performed review:** 2021-04-03 21:01

**Review time:** 17 Days and 12 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

The manuscript deserves publication in the World Journal of Gastroenterology, as it professionally reviews the involvement of the dysbiotic microbiota in the pathogenesis of IBD and highlights the potential for therapeutic modulation of the microbiome with fecal microbiota transplantation (FMT). However, the title of the manuscript does not correspond to its content. Since the manuscript is requested as the Topic Highlight article (mini-review) and not as a comprehensive review, and mainly highlights FMT as a potential microbiome-modulating strategy in patients with IBD, it is recommended to change the title to "Can fecal microbiota transplantation be a future therapeutic option for inflammatory bowel disease?", for example, or similar. The manuscript can be accepted after minor revision.



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 65865

**Title:** Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?

**Reviewer's code:** 05562053

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Associate Chief Physician, Associate Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-03-17

**Reviewer chosen by:** Man Liu

**Reviewer accepted review:** 2021-03-19 14:54

**Reviewer performed review:** 2021-04-04 16:11

**Review time:** 16 Days and 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
<https://www.wjgnet.com>

## **SPECIFIC COMMENTS TO AUTHORS**

**Q1 Please summarize the main theme of the review** A key role of the gut microbiota in the establishment and maintenance of health, as well as in the pathogenesis of disease, has been identified over the past two decades. This work provides a review of the gut microbiota may be involved in the pathogenesis of IBD, and aims to define the key classes of microbial-derived metabolites that are altered in IBD, describe the pathophysiological basis of these associations and identify future targets for precision therapeutic modulation. The author also summarize the results of current clinical trials of fecal microbiota transplantation for IBD. **Q2 The limitations and strengths** This work builds on strong scientific evidence from recent work. The text is very consistent with the objective of the work. This review bringing an important discussion in the area of gut microbiota and its relationship with IBD. However, the work is based on many studies in clinical trial. A slightly focus on animal models studies would be important. The authors could think of including two chapters: results in animal models and another results in human. **Q3 Check List** Is the English language of sufficient quality? - No Is the quality of the figure and/or table satisfactory? - Yes Does this manuscript refer only to published data? (unpublished or original data is not allowed for this article type) - Yes Does the manuscript cover the topic in an objective and analytical manner - Yes Does the reference list cover the relevant literature adequately and in an unbiased manner? - Yes Does the manuscript include recent developments? - Yes Does the review add new insights to the scholarly literature with respect to previously published reviews? - Yes

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 65865

**Title:** Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?

**Reviewer's code:** 05562061

**Position:** Peer Reviewer

**Academic degree:** MD, MS

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-03-17

**Reviewer chosen by:** Man Liu

**Reviewer accepted review:** 2021-03-21 13:00

**Reviewer performed review:** 2021-04-06 14:01

**Review time:** 16 Days and 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input checked="" type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input checked="" type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

Dear authors, The content of the current manuscript "Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?" is very similar with the content of your prior publication: Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018 Feb;11(1):1-10. doi: 10.1007/s12328-017-0813-5. Epub 2017 Dec 29. PMID: 29285689. With the exception of one paragraph or two, the content and occasionally the wording was identical between the two manuscripts. I encourage you to bring originality and up-to-date information in your future work.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 65865

**Title:** Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?

**Reviewer's code:** 00034151

**Position:** Editorial Board

**Academic degree:** FAASLD, MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** South Korea

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-03-17

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2021-04-26 06:36

**Reviewer performed review:** 2021-04-26 06:50

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

The comments are appropriately addressed in revised manuscript.